Citigroup Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $33

Benzinga · 01/07 19:47
Citigroup analyst Yigal Nochomovitz initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $33.